Refine your search

Search Results within category "Kidney & Urinary System"

Search all categories

Suggestions within category "Kidney & Urinary System"


Study matches: 5

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.


A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care.

The purpose of this study is to evaluate whether finerenone is effective and safe in treating patients with type 2 diabetes mellitus and Diabetic Kidney Disease (DKD) in addition to regular therapy.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
type 2 diabetes
clinical diagnosis of diabetic kidney disease
treatment with ACE or ARB
Exclusion Criteria:
HbA1c > 12%
uncontrolled hypertension
dialysis
current or scheduled kidney transplant
Show full eligibility criteria
NCT02545049
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Urothelial Carcinoma Lesions in the Upper Urinary Tract

This is a clinical trial, designed to determine safety & effectiveness of and patient reaction to the use of MitoGel™ in the upper urinary system of patients with non-invasive low-grade (LG), urotheilal cancer (UTUC) <iframe width="560" height="315" src="https://www.youtube.com/embed/M5GA2Csti9U?rel=0" frameborder="0" allow="autoplay; encrypted-media" allowfullscreen></iframe>
Kathleen Lehman at klehman3@pennstatehealth.psu.edu or 717-531-5930
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
At least one (1) measurable and biopsy-confirmed papillary Low Grade tumor, evaluated visually, ≤ 15 mm.
ECOG (Eastern Cooperative Oncology Group) performance status <3 (with Karnofsky >40).
Life expectancy greater than 24 months.
Adequate organ and bone marrow function as determined by routine laboratory tests
New or recurrent patients with LG, non-invasive UTUC in the pyelocalyceal system.
Exclusion Criteria:
Patient received BCG treatment for UC during the 6 months prior to Visit 1.
The patient has untreated concurrent urothelial cancer in other locations other than the target area (unless treated during screening).
Carcinoma in situ (CIS) in the past in the urinary tract.
Patient has a history of invasive urothelial carcinoma in the urinary tract during the past 5 (Five) years.
Patient is actively being treated or intends to be treated with systemic chemotherapy during the duration of the trial.
Show full eligibility criteria
NCT02793128
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients (BTCRC-GU16-051)(PSCI 17-050)

This study is being done to test the safety of combining eribulin mesylate with avelumab. It will also measure the percentage of patients whose tumor shrank after receiving eribulin mesylate in combination with avelumab. Eribulin mesylate: Eribulin mesylate is a chemotherapy that attack cells when they are dividing. Microtubules are part of the cell's structure for dividing and copying itself; like scaffolding on a building. Eribulin blocks microtubules. By blocking the microtubule structures, the cell can’t divide and grow, which causes cell death. Avelumab: Researchers have found that the body’s natural immune system sometimes cannot control cancer growth on its own. Some cancer cells and immune cells make signals that stop the body’s immune system from killing the cancer. In other words, these signals from cancer cells put the brakes on the immune system. Immunotherapy drugs help to take the brakes off the immune system. Avelumab is a drug that blocks a cell signal called PD-L1. This allows the immune system to attack and kill cancer cells.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Stage IV locally advanced node positive or metatatic-M1 positive urothelial cancer of bladder and upper tract
Histologically proven urothelial cancer of bladder with prdominant transitional cell component
Presence of measurable disease per RECIST v1.1 for solid tumors
Patients who are cisplatin ineligible as defined in the protocol
patients must be treatment naive for metastatic disease.
Exclusion Criteria:
Previous treatment with PD1 or PD-L1 inhibitor, including Avelumab
Previous systemic immunotherapy
History of another primary malignancy (except for malignancy treated with curative inten & no known active disease for greater than 5 years, adequately treated non-melanoma skin cancer, lentigo maligna or carcinoma insitu without evidence of disease
Current or prior use of immunosuppressive medication within 28 days before registration
Clinically significant cardiovascular disease
Show full eligibility criteria
N/A
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) (EA8143) (PSCI 18-025)

This study is a phase 3 study that will be comparing recurrence-free survival (RFS) between patients with locally advanced renal cell carcinoma randomly assigned to perioperative nivolumab in conjunction with radical or partial nephrectomy with patients randomized to surgery alone.
Kathleen Rizzo at krizzo@pennstatehealth.psu.edu or 717-531-0003
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
Newly Diagnosed higher risk RCC of any histology
No clinical or radiological evidence of distant metastases
No concurrent or prior systemic or local anti-cancer therapy for RCC is permitted
Age must be greater than or equal to 18 years old
ECOG Performance status must be 0 or 1
Exclusion Criteria:
Women must not be pregant or breast feeding
History of RCC that was resected with curative intent within the past 5 years
Prior or current prostate cancer is excluded
Active known or suspected autoimmune disease
Uncontrolled adrenal insufficiency
Show full eligibility criteria
NCT03055013
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.

The purpose of this study is to evaluate whether finerenone is effective and safe in treating patients with type 2 diabetes mellitus and Diabetic Kidney Disease (DKD) in addition to regular therapy.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
Hide eligibility criteria
Inclusion Criteria:
type 2 diabetes
diabetic kidney disease
treatment with ACE or ARB
Exclusion Criteria:
HbA1c > 12%
uncontrolled hypertension
dialysis
current or scheduled kidney transplant
Show full eligibility criteria
NCT02540993
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA